Clinical trial
Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study
NCT02754297 is registered in ClinicalTrials.gov with CHU de Quebec-Universite Laval as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study
- Lead sponsor
- CHU de Quebec-Universite Laval
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 12, 2016
- Completion date
- April 12, 2029
- Enrollment
- 275 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.